W. Garvey to Glucose Intolerance
This is a "connection" page, showing publications W. Garvey has written about Glucose Intolerance.
Connection Strength
0.874
-
Estimation of resting energy expenditure considering effects of race and diabetes status. Diabetes Care. 2004 Jun; 27(6):1405-11.
Score: 0.225
-
Canagliflozin extends life span in genetically heterogeneous male but not female mice. JCI Insight. 2020 11 05; 5(21).
Score: 0.175
-
APPLICATION OF THE AACE/ACE ADVANCED FRAMEWORK FOR THE DIAGNOSIS OF OBESITY AND CARDIOMETABOLIC DISEASE STAGING IN A GENERAL POPULATION FROM 3 REGIONS OF VENEZUELA: THE VEMSOLS STUDY RESULTS. Endocr Pract. 2018 Jan; 24(1):6-13.
Score: 0.143
-
AP2-NR4A3 transgenic mice display reduced serum epinephrine because of increased catecholamine catabolism in adipose tissue. Am J Physiol Endocrinol Metab. 2016 Jul 01; 311(1):E69-81.
Score: 0.129
-
The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring). 2014 Jan; 22(1):110-8.
Score: 0.107
-
Clinical implications of the insulin resistance syndrome. Clin Cornerstone. 1998; 1(3):13-28.
Score: 0.036
-
Gestational diabetes mellitus and gene mutations which affect insulin secretion. Diabetes Res Clin Pract. 1997 Jun; 36(3):135-41.
Score: 0.035
-
Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophages. Atherosclerosis. 2013 May; 228(1):124-35.
Score: 0.026